Pyridoxine increases nitric oxide biosynthesis in human platelets

International Journal for Vitamin and Nutrition Research

Volumn 79, Issue 2, 2009, Pages 95-103

  Wu, Yong ^a   Liu, Yuan ^a   Han, Yi ^b   Cui, Bota ^a   Mi, Qiongyu ^a   Huang, Yan ^a   Wang, Li ^a   Jiang, Qin ^a   Chen, Qi ^a   Liu, Naifeng ^b   Ferro, Albert ^c   Ji, Yong ^a,c  

^a NANJING MEDICAL UNIVERSITY   (China)

^b SOUTHEAST UNIVERSITY   (China)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

5 monophosphate (cGMP); Cyclic guanosine 3 ; Nitric oxide synthase(NOS); Platelet aggregation; Platelets; Pyridoxine

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ADENOSINE DIPHOSPHATE; CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PYRIDOXINE; SERINE; THROMBIN;

ADULT; ARTICLE; BIOSYNTHESIS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NORMAL HUMAN; RADIOIMMUNOASSAY; THROMBOCYTE; THROMBOCYTE AGGREGATION; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOSINE DIPHOSPHATE; ADULT; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; CYCLIC GMP; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FEMALE; HUMANS; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHORYLATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDOXINE; THROMBIN; YOUNG ADULT;

EID: 76749132156     PISSN: 03009831     EISSN: None     Source Type: Journal    
DOI: 10.1024/0300-9831.79.2.95     Document Type: Article

References (27)

1. Ahrens, I., Bode, C. and Peter, K. (2005) Inhibition of platelet activation and aggregation. Handbook. Exp. Pharmacol. 170, 443-462.
2. Anerson, T.J. (2003) Nitric oxide, atherosclerosis and the clinical relevance of endothelial dysfunction. Heart Failure Rev. 8, 71 -86.
3. Ault, K.A., Cannon, C.P., Mitchell. J., Tracy, R.P., Novotny, W.F., Reimann, J.D. and Braunwald, E. (1999) Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction. J. Am. Coll. Cardiol. 33, 634-639.
4. Colwell, J.A., Lopes-Virella, M. and Halushka, P.V. (1981) Pathogenesis of atherosclerosis in diabetes mellitus. Diabetes Care 4, 121-133.
5. Colwell, J.A., Winocour, P.D., Lopes-Virella, M. and Halushka, P.V. (1983) New concepts about the pathogenesis of atherosclerosis in diabetes mellitus. Am. J. Med. 75, 67-80.
6. Dimmeler, S., Assmus, B., Hermann, C., Haendeler, J. and Zeiher, A.M. (1998) Fluid shear stress stimulates phosphorylation of Akt in human endothelial cells: involvement in suppression of apoptosis. Circ. Res. 83, 334- 41.
7. Dimmeler, S., Fleming, I., Fisslthaler, B., Hermann, C., Busse, R. and Zeiher, A.M. (1999) Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399, 601-605.
8. Fulton, D., Gratton, J.P., McCabe, T.J., Fontana, J., Fujio, Y.,Walsh, K., Franke, T.F., Papapetropoulos, A. and Sessa, W.C. (1999) Regulation of endotheliumderived nitric oxide production by the protein kinase Akt. Nature 399, 597-601.
9. Gawaz, M., Neumann, F.J.,Dickfeld, T., Reininger, A., Adelsberger, H., Gebhardt, A. and Schömig, A. (1997) Vitronectin receptor (alpha(v)beta3) mediates platelet adhesion to the luminal aspect of endothelial cells: implications for reperfusion in acute myocardial infarction. Circulation 96, 1809-1818.
10. Gkaliagkousi, E., Ritter, J. and Ferro, A. (2007) Platelet-derived nitric oxide signaling and regulation. Circ. Res. 101, 654-662.
11. Hansson, G.K. (2005) Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352, 1685-1695.
12. Hofmann, M.A., Lalla, E., Lu, Y., Gleason, M.R., Wolf, B.M., Tanjin, N., Ferran, L.J. Jr., Kohl, B., Rao, V., Kisiel, W., Stern, D.M. and Schmidt, A.M. (2001) Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J. Clin. Invest. 107, 675-683.
13. Ji, Y., Han, Y., Diao, J., Huang, Y., Chen, Q. and Ferro, A. (2003) Rabbit aortic endothelial dysfunction by low-density lipoprotein is attenuated by L-arginine, L-ascorbate and pyridoxine. Br. J. Pharmacol. 140, 1272-1282.
14. Ji, Y., Han, Y., Diao, J., Huang, Y., Chen, Q., and Ferro, A. (2004) Inhibition of endothelial nitric oxide generation by low-density lipoprotein is partially prevented by L-arginine and L-ascorbate. Atherosclerosis 176, 345-353.
15. Ji, Y., Diao, J., Han, Y., Huang, Y., Bai, H., Chen, Q., Fan, L. and Ferro, A. (2006) Pyridoxine prevents dysfunction of endothelial cell nitric oxide production in response to low-density lipoprotein. Atherosclerosis 188, 84-94.
16. Jorgensen, L. (2005) ADP-induced platelet aggregation in the microcirculation of pig myocardium and rabbit kidneys. J. Thromb. Haemost. 3, 1119-1124.
17. Jorgensen, L. (2006) The role of platelets in the initial stages of atherosclerosis. J. Thromb. Haemost. 4, 1443-1449.
18. 2-treated U937 monocytes. Free Radical Biol. Med. 36, 423- 428.
19. Krishnamurthi, S., Westwick, J. and Kakkar, V.V. (1982) Effect of pyridoxal 5′-phosphate (PALP) on human platelet aggregation, dense granule release and thromboxane B2 generation - role of Schiff base formation. Thromb. Haemost. 48, 136-141.
20. Miner, S.E., Cole, D.E., Evrovski, J., Forrest, Q., Hutchison, S., Holmes, K. and Ross, H.J. (2001) Pyridoxine improves endothelial function in cardiac transplant recipients. J. Heart Lung Transplant 20, 964-969.
21. Randriamboavonjy, V. and Fleming, I. (2005) Endothelial nitric oxide synthase (eNOS) in platelets: how is it regulated and what is it doing there? Pharmacol. Rep. 57, 59-65.
22. Ross, R. (1999) Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340, 115-126.
23. Schafer, A., Alp, N.J., Cai, S., Lygate, C.A., Neubauer, S., Eigenthaler, M., Bauersachs, J. and Channon, K.M. (2004) Reduced Vascular NO bioavailability in diabetes increases platelet activation in vivo. Arterioscler. Thromb. Vasc. Biol. 24, 1720-1726.
24. Takahashi, S. and Mendelsohn, M.E. (2003) Synergistic activation of endothelial nitric-oxide synthase(eNOS) by HSP90 and Akt: calcium-independent eNOS activation involves formation of an HSP90-Akt-CaM-bound eNOS complex. J. Biol. Chem. 278, 30821 -30827.
25. Wagner, D.D. and Burger, P.C. (2003) Platelets in inflammation and thrombosis. Arterioscler. Thromb. Vasc. Biol. 23, 2131-2137.
26. Zhang, W., Yao, J., Pham, V.,Whitney, T., Forese, D., Friesen, A., Stang, L., Xu, C., Shuaib, A., Diakur, J.M. and Haque, W. (2004) Pyridoxine as a template for the design of antiplatelet agents. Bioorg. Med. Chem. Lett. 14, 4747-4750.
27. Zhou, J., Moller, J., Riskes-Hoitinga, M., Larsen, M.L., Austin, R.C. and Falk, E.(2003) Effects of vitamin supplement and hyperhomocysteinemia on atherosclerosis in apoE-deficient mice. Atherosclerosis 168, 255-262.